CAS 1801333-55-0

Formula: C23H24ClFN4O3

InChI: InChI=1S/C23H24ClFN4O3/c1-13(2)17-10-27-21(16-7-14(24)3-4-19(16)25)8-22(17)29-20-5-6-26-9-18(20)23(32)28-15(11-30)12-31/h3-10,13,15,30-31H,11-12H2,1-2H3,(H,28,32)(H,26,27,29)

InChI key: IPBLCOKXDQHSQW-UHFFFAOYSA-N

SMILES: CC(C)C1=CN=C(C=C1NC2=C(C=NC=C2)C(=O)NC(CO)CO)C3=C(C=CC(=C3)Cl)F

PF-06952229

CAS: 1801333-55-0

PF-06952229

Purity: ≥98%

Molecular weight: 458.91g/mol

Ref: 54-BUP04138

4-((2-(5-Chloro-2-fluorophenyl)-5-isopropylpyridin-4-yl)amino)-N-(1,3-dihydroxypropan-2-yl)nicotinamide

CAS: 1801333-55-0

Formula: C₂₃H₂₄ClFN₄O₃

Purity: 99.92%

Color and Shape: Solid

Molecular weight: 458.9131

Ref: IN-DA01V748

PF-06952229

CAS: 1801333-55-0

PF-06952229 is an inhibitor analog that targets kinase enzymes. It has been shown to be effective in reducing the activity of certain kinases found in human urine and cancer cells, making it a promising candidate for anticancer therapy. This inhibitor selectively induces apoptosis, or programmed cell death, in tumor cells by inhibiting specific protein kinases that are involved in cancer cell growth and proliferation. PF-06952229 has also demonstrated efficacy against oseltamivir-resistant influenza viruses. This compound is highly selective and does not affect other kinases or proteins, making it a safe and effective treatment option for various types of cancer.

Formula: C₂₃H₂₄ClFN₄O₃

Purity: Min. 95%

Molecular weight: 458.9 g/mol

Ref: 3D-BXC33355

PF-06952229

CAS: 1801333-55-0

PF-06952229 is a selective inhibitor of TGFβRI. PF-06952229 can be used in studies about the treatment of solid tumors, specifically metastatic breast cancer.

Formula: C₂₃H₂₄ClFN₄O₃

Purity: 99.73% - 99.73%

Color and Shape: Solid

Molecular weight: 458.913

Ref: TM-T12433